DSG2 and arrhythmogenic right ventricular cardiomyopathy: Another cohort study identified anti-desmoglein-2 (Anti-DSG2) antibodies as a sensitive and specific biomarker for arrhythmogenic right ventricular cardiomyopathy (ARVC).